Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
ABOUT
PRICE TARGET
UPCOMING EARNINGS
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$9.79 ▲ UP 2.73% (+$0.26)About Pharming Group N.V.
https://www.pharming.com ↗Pharming Group N.V. is a biopharmaceutical company developing protein replacement therapies and precision medicines for rare diseases, with products like Ruconest for hereditary angioedema and collaborations with Novartis and Orchard Therapeutics.
INDUSTRY
A PRODUCT PHARMING GROUP N.V. IS KNOWN FOR
Joenja® is the first FDA-approved oral PI3Kδ inhibitor for APDS in patients 12+, marking a significant milestone for Pharming Group with a successful U.S. launch and strong initial patient uptake.
Pharming Group in 2025
Pharming Group Exceeds 2025 Revenue Guidance with 27% Growth, Signaling Strong Commercial Success
Pharming Group announced preliminary full-year 2025 revenues of approximately $376 million, surpassing its upwardly revised guidance and representing about 27% growth over 2024. This significant financial milestone was driven by the strong and growing demand for its commercial products, RUCONEST® and Joenja®, putting the company in a significant spotlight for investors.
Pharming Group Initiates Organizational Restructuring to Reduce Costs and Accelerate Growth
Pharming Group announced a significant organizational restructuring in late 2025 aimed at optimizing capital allocation and enhancing operational efficiency. The plan involves a strategic redesign of the company's structure and a reduction in workforce to lower administrative expenses and focus resources on growth drivers.
RATINGS SNAPSHOT
Overall rating: B-
MOST RECENT ANALYST GRADES
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 BMRN | $54.64 | COMPARE |
 IONS | $43.51 | COMPARE |
 TNGX | $21.45 | COMPARE |
 PHVS | $31.00 | COMPARE |
 BCRX | $8.30 | COMPARE |
 FTRE | $21.52 | COMPARE |
 PVLA | $128.77 | COMPARE |
 NTLA | $12.01 | COMPARE |